Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Hepatology ; 57(3): 1238-49, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23080298

ABSTRACT

UNLABELLED: Toll-like receptors (TLRs) function as key regulators of liver fibrosis and are able to modulate the fibrogenic actions of nonparenchymal liver cells. The fibrogenic signaling events downstream of TLRs on Kupffer cells (KCs) and hepatic stellate cells (HSCs) are poorly defined. Here, we describe the MAP3K tumor progression locus 2 (Tpl2) as being important for the activation of extracellular regulated kinase (ERK) signaling in KCs and HSCs responding to stimulation of TLR4 and TLR9. KCs lacking Tpl2 display defects with TLR induction of cytokines interleukin (IL)-1ß, IL-10, and IL-23. tpl2(-/-) HSCs were unable to increase expression of fibrogenic genes IL-1ß and tissue inhibitor of metalloproteinase 1 (TIMP-1), with the latter being the result of defective stimulation of TIMP-1 promoter activity by TLRs. To determine the in vivo relevance of Tpl2 signaling in liver fibrosis, we compared the fibrogenic responses of wild-type (WT) and tpl2(-/-) mice in three distinct models of chronic liver injury. In the carbon tetrachloride and methionine-choline-deficient diet models, we observed a significant reduction in fibrosis in mice lacking Tpl2, compared to WT controls. However, in the bile duct ligation model, there was no effect of tpl2 deletion, which may reflect a lesser role for HSCs in wounding response to biliary injury. CONCLUSION: We conclude that Tpl2 is an important signal transducer for TLR activation of gene expression in KCs and HSCs by the ERK pathway and that suppression of its catalytic activity may be a route toward suppressing fibrosis caused by hepatocellular injuries. (HEPATOLOGY 2013).


Subject(s)
Hepatic Stellate Cells/physiology , Liver Cirrhosis/metabolism , MAP Kinase Kinase Kinases/metabolism , MAP Kinase Signaling System/physiology , Proto-Oncogene Proteins/metabolism , Tissue Inhibitor of Metalloproteinase-1/genetics , Animals , Cells, Cultured , Cytokines/metabolism , Hepatic Stellate Cells/cytology , Hepatocytes/cytology , Hepatocytes/physiology , Kupffer Cells/cytology , Kupffer Cells/physiology , Liver Cirrhosis/genetics , Liver Cirrhosis/pathology , MAP Kinase Kinase Kinases/genetics , Macrophages/cytology , Macrophages/physiology , Male , Mice , Mice, Knockout , Proto-Oncogene Proteins/genetics , Tissue Inhibitor of Metalloproteinase-1/metabolism , Toll-Like Receptor 4/metabolism , Toll-Like Receptor 9/metabolism , Transcription, Genetic/physiology
2.
Cancer Sci ; 103(1): 88-99, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21943109

ABSTRACT

Alcoholic extract of Piper betle (Piper betle L.) leaves was recently found to induce apoptosis of CML cells expressing wild type and mutated Bcr-Abl with imatinib resistance phenotype. Hydroxy-chavicol (HCH), a constituent of the alcoholic extract of Piper betle leaves, was evaluated for anti-CML activity. Here, we report that HCH and its analogues induce killing of primary cells in CML patients and leukemic cell lines expressing wild type and mutated Bcr-Abl, including the T315I mutation, with minimal toxicity to normal human peripheral blood mononuclear cells. HCH causes early but transient increase of mitochondria-derived reactive oxygen species. Reactive oxygen species-dependent persistent activation of JNK leads to an increase in endothelial nitric oxide synthase-mediated nitric oxide generation. This causes loss of mitochondrial membrane potential, release of cytochrome c from mitochondria, cleavage of caspase 9, 3 and poly-adenosine diphosphate-ribose polymerase leading to apoptosis. One HCH analogue was also effective in vivo in SCID mice against grafts expressing the T315I mutation, although to a lesser extent than grafts expressing wild type Bcr-Abl, without showing significant bodyweight loss. Our data describe the role of JNK-dependent endothelial nitric oxide synthase-mediated nitric oxide for anti-CML activity of HCH and this molecule merits further testing in pre-clinical and clinical settings.


Subject(s)
Apoptosis/drug effects , Drug Resistance, Neoplasm/drug effects , Eugenol/analogs & derivatives , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , MAP Kinase Kinase 4/metabolism , Mitochondria/drug effects , Nitric Oxide Synthase Type III/metabolism , Piper betle/chemistry , Reactive Oxygen Species/metabolism , Animals , Antineoplastic Agents/pharmacology , Benzamides , Blotting, Western , Eugenol/chemistry , Eugenol/pharmacology , Flow Cytometry , Fusion Proteins, bcr-abl/genetics , Humans , Imatinib Mesylate , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolism , Male , Membrane Potential, Mitochondrial/drug effects , Mice , Mice, Nude , Mice, SCID , Mitochondria/metabolism , Nitric Oxide/metabolism , Phosphorylation/drug effects , Piperazines/pharmacology , Plant Extracts/pharmacology , Plant Leaves/chemistry , Pyrimidines/pharmacology , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...